GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Novo Integrated Sciences Inc (NAS:NVOS) » Definitions » Enterprise Value

Novo Integrated Sciences (Novo Integrated Sciences) Enterprise Value : $15.76 Mil (As of May. 11, 2024)


View and export this data going back to 2005. Start your Free Trial

What is Novo Integrated Sciences Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Novo Integrated Sciences's Enterprise Value is $15.76 Mil. Novo Integrated Sciences's EBIT for the trailing twelve months (TTM) ended in Feb. 2024 was $-8.97 Mil. Therefore, Novo Integrated Sciences's EV-to-EBIT ratio for today is -1.76.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Novo Integrated Sciences's Enterprise Value is $15.76 Mil. Novo Integrated Sciences's EBITDA for the trailing twelve months (TTM) ended in Feb. 2024 was $-6.66 Mil. Therefore, Novo Integrated Sciences's EV-to-EBITDA ratio for today is -2.37.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Novo Integrated Sciences's Enterprise Value is $15.76 Mil. Novo Integrated Sciences's Revenue for the trailing twelve months (TTM) ended in Feb. 2024 was $13.66 Mil. Therefore, Novo Integrated Sciences's EV-to-Revenue ratio for today is 1.15.


Novo Integrated Sciences Enterprise Value Historical Data

The historical data trend for Novo Integrated Sciences's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Integrated Sciences Enterprise Value Chart

Novo Integrated Sciences Annual Data
Trend Dec14 Dec15 Dec16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23
Enterprise Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 100.29 96.14 53.79 62.47 25.80

Novo Integrated Sciences Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.13 22.96 25.80 23.45 15.59

Competitive Comparison of Novo Integrated Sciences's Enterprise Value

For the Medical Care Facilities subindustry, Novo Integrated Sciences's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novo Integrated Sciences's Enterprise Value Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Novo Integrated Sciences's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Novo Integrated Sciences's Enterprise Value falls into.



Novo Integrated Sciences Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Novo Integrated Sciences's Enterprise Value for the fiscal year that ended in Aug. 2023 is calculated as

Novo Integrated Sciences's Enterprise Value for the quarter that ended in Feb. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Novo Integrated Sciences  (NAS:NVOS) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Novo Integrated Sciences's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=15.761/-8.965
=-1.76

Novo Integrated Sciences's current Enterprise Value is $15.76 Mil.
Novo Integrated Sciences's EBIT for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.97 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Novo Integrated Sciences's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=15.761/-6.661
=-2.37

Novo Integrated Sciences's current Enterprise Value is $15.76 Mil.
Novo Integrated Sciences's EBITDA for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.66 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Novo Integrated Sciences's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=15.761/13.658
=1.15

Novo Integrated Sciences's current Enterprise Value is $15.76 Mil.
Novo Integrated Sciences's Revenue for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $13.66 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Novo Integrated Sciences Enterprise Value Related Terms

Thank you for viewing the detailed overview of Novo Integrated Sciences's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Novo Integrated Sciences (Novo Integrated Sciences) Business Description

Traded in Other Exchanges
N/A
Address
11120 NE 2nd Street, Suite 100, Bellevue, WA, USA, 98004
Novo Integrated Sciences Inc is a medical care company. It provides specialized physiotherapy, chiropractic care, occupational therapy, eldercare, laser therapeutics, massage therapy, acupuncture, neurological functions, kinesiology, and others. It has two reportable segments: healthcare services which generates majority of the revenue, and product sales.
Executives
Sarfaraz Ali director C/O NOVO INTEGRATED SCIENCES, INC.,, 11120 NE 2ND STREET, SUITE 100, BELLEVUE WA 98004
Robert Letterio Oliva director 115 BELFIELD RD, TORONTO A6 L0J 1C0
Sterling M. Jimenez officer: Principal Financial Officer C/O NOVO INTEGRATED SCIENCES, INC.,, 11120 NE 2ND STREET, SUITE 100, BELLEVUE WA 98004
Michael Ross Pope director 1045 PROGRESS CIRCLE, LAWRENCEVILLE, GEORGIA GA 30043
Alex Flesias director 41 LANDMARK COURT, UNIONVILLE A6 L3R 9N7
Michael Joseph Gaynor director 49 BALMORAL ST, KEMPTVILLE A6 K0G 1J0
Robert Mattacchione director, 10 percent owner, officer: Chief Executive Officer 79 SELVAPIANO CRES, WOODBRIDGE A6 L4H 0X1
Pierre Joseph Dalcourt director, 10 percent owner 35 BRYANT ST , BOX 2230, HEARST A6 P0L 1N0
Christopher Mehlin David director, officer: President 10425 SE 22ND ST., BELLEVUE WA 98004
Thomas Edward Bray officer: Principal Financial Officer C/O NOVO INTEGRATED SCIENCES, INC., 11120 NE 2ND STREET, SUITE 100, BELLEVUE WA 98004
Rebecca Aw Mcdonald officer: Chief Accounting Officer 1301 INTERNATIONAL SPEEDWAY BLVD., DELAND FL 32724
James Jr Teters director 1200 FLIGHTLINE BLVD, STE 5, DELAN FL 32724
Phyllis Rouse officer: secretary 1200 FLIGHLINE BLVD,, SUITE 5, DELAND FL 32724
Jay Hilden officer: President & CEO 1200 FLIGHLINE BLVD,, SUITE 5, DELAND FL 32724
Robert Adamo director 1200 FLIGHTLINE BOULEVARD, SUITE 5, DELAND FL 32724